RECRUITING

Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed study is a quality improvement initiative designed to rigorously evaluate new variations of UCLA Health's proton pump inhibitor (PPI) order panels, building on internal quality improvement efforts to optimize prescribing workflows within the Electronic Health Record (EHR). PPIs are notoriously overprescribed, and the study team has identified that the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether modifying defaulted prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority. This evaluation of PPI order panel variations is embedded within UCLA's existing EHR system, ensuring that changes are tested pragmatically within routine workflows. The study aims to determine whether small adjustments to the order panel can better align prescribing patterns with clinical best practices while maintaining physician autonomy.

Official Title

Quality Improvement Initiative Leveraging Electronic Healthcare Records to Reduce Inappropriate Proton Pump Inhibitors (PPI) Prescribing at UCLA.

Quick Facts

Study Start:2025-05
Study Completion:2026-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06998966

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * UCLA Health primary care physicians who have a clinical full-time equivalency of at least 25%.
  1. * Physicians with a clinical full-time equivalency of less than 25%

Contacts and Locations

Study Contact

Katelyn Clinical Research Coordinator
CONTACT
310-267-5250
katenguyen@mednet.ucla.edu

Study Locations (Sites)

UCLA Health System
Los Angeles, California, 90024
United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05
Study Completion Date2026-07

Study Record Updates

Study Start Date2025-05
Study Completion Date2026-07

Terms related to this study

Keywords Provided by Researchers

  • Proton Pump Inhibitors
  • Quality Improvement
  • Healthcare Utilization
  • Clinical Decision Support
  • resource utilization

Additional Relevant MeSH Terms

  • Prescription Optimization
  • Clinical Decision Support
  • Proton Pump Inhibitor (PPI) Overuse